ENXTAM:DSFIRChemicals
Should DSM-Firmenich's Q3 EBITDA Growth and Business Divestment Shape Investor Decisions? (ENXTAM:DSFIR)
On October 30, 2025, DSM-Firmenich reported solid third-quarter growth, a significant increase in Adjusted EBITDA, and provided updates on its ongoing €1 billion share repurchase program and the planned exit from its Animal Nutrition & Health business, with the divestment on track to conclude in the fourth quarter.
The company also revised its full-year outlook due to unfavorable foreign exchange effects and continued volatility in vitamins, reflecting the operational challenges of its...